NCT02249299View on ClinicalTrials.gov

Experimental Medicine in ADHD - Cannabinoids

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

December 31, 2015

Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
DRUG

Sativex Oromucosal Spray

Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).

DRUG

Placebo

Trial Locations (1)

SE5 8AF

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London

All Listed Sponsors
collaborator

South London and Maudsley NHS Foundation Trust

OTHER

lead

King's College London

OTHER

NCT02249299 - Experimental Medicine in ADHD - Cannabinoids | Biotech Hunter | Biotech Hunter